A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)
Number of participants with adverse events (AE) and serious adverse events (SAE), Objective response rate (ORR)
Endpoint detail
Best Overall Response(BOR), Change in Target Lesion Tumor Size, Progression free survival (PFS), Disease Control Rate(DCR) at 12 Weeks, Duration Of Response (DoR), Overall Survival(OS), Serum concentration, Maximum plasma drug concentration (Cmax), Immunogenicity of study interventions in participants receiving treatment
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.